Skip to main content

Immunome Inc 8-K, filed Nov 9, 2026

Immunome Inc. (IMNM)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

Immunome Inc filed this 8-K on November 9, 2026.

Immunome reported a net loss of $85.8 million for the quarter ended September 30, 2026, while varegacestat’s PDUFA target action date is April 28, 2027. IM-1340 received IND clearance, with its Phase 1 trial expected to start by year-end 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits